Literature DB >> 22846337

The role of osteoclasts and tumour-associated macrophages in osteosarcoma metastasis.

Liliana Endo-Munoz1, Andreas Evdokiou, Nicholas A Saunders.   

Abstract

Osteosarcoma (OS) is the most common primary bone tumour in the paediatric age group. Treatment-refractory pulmonary metastasis continues to be the major complication of OS, reducing the 5-year survival rate for these patients to 10-20%. The mechanisms underlying the metastatic process in OS are still unclear, but undoubtedly, a greater understanding of the factors and interactions involved in its regulation will open new and much needed opportunities for therapeutic intervention. Recent published data have identified a new role for bone-specific macrophages (osteoclasts) and tumour-associated macrophages (TAMs), in OS metastasis. In this review we discuss the contribution of TAMs and osteoclasts in the establishment and maintenance of secondary metastatic lesions, and their novel role in the prevention of metastatic disease in a primary bone cancer such as osteosarcoma.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22846337     DOI: 10.1016/j.bbcan.2012.07.003

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  37 in total

Review 1.  Bone microenvironment signals in osteosarcoma development.

Authors:  Arantzazu Alfranca; Lucia Martinez-Cruzado; Juan Tornin; Ander Abarrategi; Teresa Amaral; Enrique de Alava; Pablo Menendez; Javier Garcia-Castro; Rene Rodriguez
Journal:  Cell Mol Life Sci       Date:  2015-05-03       Impact factor: 9.261

Review 2.  Progress in the chemotherapeutic treatment of osteosarcoma.

Authors:  Ya Zhang; Jingqing Yang; Na Zhao; Cao Wang; Santosh Kamar; Yonghong Zhou; Zewei He; Jifei Yang; Bin Sun; Xiaoqian Shi; Lei Han; Zuozhang Yang
Journal:  Oncol Lett       Date:  2018-09-12       Impact factor: 2.967

3.  Nonsurgical giant cell tumour of the tendon sheath or of the diffuse type: are MRI or 18F-FDG PET/CT able to provide an accurate prediction of long-term outcome?

Authors:  Laurent Dercle; Roland Chisin; Samy Ammari; Quentin Gillebert; Monia Ouali; Cyril Jaudet; Jean-Pierre Delord; Lawrence Dierickx; Slimane Zerdoud; Martin Schlumberger; Frédéric Courbon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-11-01       Impact factor: 9.236

4.  L-MTP-PE and zoledronic acid combination in osteosarcoma: preclinical evidence of positive therapeutic combination for clinical transfer.

Authors:  Kevin Biteau; Romain Guiho; Mathias Chatelais; Julien Taurelle; Julie Chesneau; Nadège Corradini; Dominique Heymann; Françoise Redini
Journal:  Am J Cancer Res       Date:  2016-02-15       Impact factor: 6.166

5.  Inhibition of macrophage polarization prohibits growth of human osteosarcoma.

Authors:  Qiang Xiao; Xuepu Zhang; Yuexin Wu; Yu Yang
Journal:  Tumour Biol       Date:  2014-05-06

6.  MicroRNA 181a improves proliferation and invasion, suppresses apoptosis of osteosarcoma cell.

Authors:  Zhu Jianwei; Liu Fan; Liu Xiancheng; Bai Enzhong; Li Shuai; Li Can
Journal:  Tumour Biol       Date:  2013-06-06

7.  Depletion of ALX1 causes inhibition of migration and induction of apoptosis in human osteosarcoma.

Authors:  Mingfu Yang; Yong Pan; Yue Zhou
Journal:  Tumour Biol       Date:  2015-03-04

Review 8.  Canine sarcomas as a surrogate for the human disease.

Authors:  Daniel L Gustafson; Dawn L Duval; Daniel P Regan; Douglas H Thamm
Journal:  Pharmacol Ther       Date:  2018-03-09       Impact factor: 12.310

9.  Magnetic Resonance Imaging of Tumor-Associated Macrophages: Clinical Translation.

Authors:  Maryam Aghighi; Ashok J Theruvath; Anuj Pareek; Laura L Pisani; Raphael Alford; Anne M Muehe; Tarsheen K Sethi; Samantha J Holdsworth; Florette K Hazard; Dita Gratzinger; Sandra Luna-Fineman; Ranjana Advani; Sheri L Spunt; Heike E Daldrup-Link
Journal:  Clin Cancer Res       Date:  2018-05-15       Impact factor: 12.531

Review 10.  Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies.

Authors:  Ingrid Lilienthal; Nikolas Herold
Journal:  Int J Mol Sci       Date:  2020-09-19       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.